Invesco Exchange-Traded Self-Indexed Fund Trust has released its latest financial report, highlighting a total asset value exceeding $1 billion. This substantial figure underscores the fund's ongoing stability and resilience within the competitive investment management landscape.
According to the filing dated October 30, 2026, the fund's total assets stand at approximately $1,001,367,379, while its total liabilities are reported at $18,132,621. This results in a net asset value of about $983,234,758, indicating a solid financial position.
Background
Invesco Exchange-Traded Self-Indexed Fund Trust, incorporated in Delaware, operates under the Central Index Key (CIK) number 0001657201. The fund primarily focuses on investment strategies that leverage exchange-traded funds (ETFs). It has undergone name changes in the past, previously known as PowerShares Exchange-Traded Self-Indexed Fund Trust.
What the Filing Says
The filing, identified by accession number 0001657201-26-000787, provides detailed insights into the fund's financial status as of August 31, 2026. It states, "Total assets of the fund are $1,001,367,379.16, with net assets amounting to $983,234,757.99." This information emphasizes the fund's robust asset management capabilities.
Impact
This financial disclosure may have implications for investors and stakeholders within the investment management sector. The reported figures reflect not only Invesco's health but also its competitive positioning against other firms in the industry. Competitors will likely analyze these results to gauge their own performance in relation to Invesco's growth.
What's Next
The filing does not specify any upcoming actions or events related to the fund's financial status. Investors and analysts will continue to monitor future filings for further developments.
Read Next
Jefferies CEO Handler Reports Stock Transactions in SEC Filing
Brophy Michael Burkes sells 3,084 shares of Natera stock
Glenbrook Capital Management Boosts Stake in SenesTech
OS Therapies grants stock options to Chief Medical Officer
Belite Bio CEO Lin Yu-Hsin Vests 5,000 Shares
Chen Wan-Shan Reports Share Transaction for Belite Bio






